Contents
Mpox’s Status in the United States
While the new strain of mpox has not been detected in the U.S., the country remains on high alert. The Centers for Disease Control and Prevention (CDC) has issued a travel notice and health alert for the more potent strain observed in Congo and neighboring countries. Although there are a few cases of a less severe strain reported weekly, the risk of the new strain spreading within the U.S. is currently considered very low.
The 2022 Outbreak and Its Lessons
Reflecting on the 2022 outbreak provides valuable insights. The mpox clade II strain reached the U.S. during the spring of that year, leading to several hundred cases by August. The outbreak was primarily concentrated in major urban centers and coincided with social events, which facilitated its spread. Although the outbreak was declared over by early 2023, it served as a critical learning point for handling such diseases in populous settings.
Transmission, Symptoms, and Treatment
Transmission of mpox is predominantly through close contact with the infected. The symptoms often resemble the flu, including fever, headache, and swollen lymph nodes, and are accompanied by distinctive pus-filled skin lesions. These lesions progress through several stages before healing, and the illness can last from two to four weeks.
Vaccination remains the most effective prevention strategy. The JYNNEOS vaccine, which protects against both clade I and II, has shown high efficacy. However, there are challenges with vaccine uptake, particularly concerning the completion of the two-dose series.
Final Thoughts
As mpox continues to challenge global health responses, the importance of preparedness, timely vaccination, and international cooperation cannot be overstated. While the U.S. may not currently face the brunt of this outbreak, the situation underscores the ever-present need for vigilance in a connected world where diseases know no borders.
